BiotechTubeBiotechTube
Home/Adlai Nortye/Dr. Markus Metz
DM

Dr. Markus Metz

Chief Development Officer

Adlai Nortye

Therapeutic Areas

Oncology

Adlai Nortye Pipeline

DrugIndicationPhase
Buparlisib (AN2025)Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Phase 3
AN0025 (Eganelisib)Locally Advanced Rectal Cancer (LARC)Phase 1b/2
AN4005Advanced Solid TumorsPreclinical
AN3025Advanced Solid TumorsPreclinical
AN1025Advanced Solid TumorsPreclinical
AN9025Advanced Solid TumorsDiscovery

Leadership Team at Adlai Nortye

DL
Dr. Lars Birgerson
President and Chief Executive Officer
DC
Dr. Carsten Brunn
Former President and Chief Executive Officer
DM
Dr. Michael Humphries
Chief Business Officer
DF
Dr. Francisco Robert
Chief Medical Officer
PS
Per Samuelsson
Chairman of the Board of Directors
DJ
Dr. John de Groot
Board Director
KX
Katherine Xu
Board Director
DE
Dr. Ezra Cohen
Scientific Advisory Board Member
DD
Dr. David Hong
Scientific Advisory Board Member
DJ
Dr. Joshua Brody
Scientific Advisory Board Member
View full Adlai Nortye profile